ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Publications Pegloprastide Publications Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study Ann Surg Oncol. – October 2017 Sensitive in vivo Visualization of Breast Cancer Using Ratiometric Protease-activatable Fluorescent Imaging Agent, AVB-620 Theranostics – August 2017 Platform Technology Early detection of squamous cell carcinoma in carcinogen induced oral cancer rodent model by ratiometric activatable cell penetrating peptides Oral Oncol. – August 2017 Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice Otolaryngol Head Neck Surg. – October 2014 Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides Cancer Res. – January 2013 Ratiometric activatable cell-penetrating peptides provide rapid in vivo readout of thrombin activation Angew Chem Int Ed Engl – January 2013 Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival Proc Natl Acad Sci U.S.A – March 2010 Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases Proc Natl Acad Sci U.S.A – March 2010 In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer Integr Biol (Camb) – June 2009 Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides Integr Biol (Camb) – June 2009 Tumor imaging by means of proteolytic activation of cell-penetrating peptides Proc Natl Acad Sci U.S.A – December 2004 HOME ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Copyright © Avelas Biosciences | Website by AshWebStudio